O
2.57
-0.17 (-6.20%)
| Previous Close | 2.74 |
| Volume | 419,970 |
| Price / Sales | 184.26 |
| Price / Book | 2.11 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,653.85% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -12.20% |
| Total Debt/Equity (MRQ) | 24.34% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -49.55 M |
| Levered Free Cash Flow (TTM) | -27.61 M |
| Return on Assets (TTM) | -31.37% |
| Return on Equity (TTM) | -36.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ovid Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.8 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.38 |
Select this tab to load the latest available analysis.
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 55.97% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |